Neuroleptic malignant syndrome in advanced Parkinson's disease.
Neuroleptic malignant syndrome is a serious complication of levodopa withdrawal in patients with Parkinson's disease. We report a patient with advanced parkinsonism who developed neuroleptic malignant syndrome in the setting of inadequate levodopa intake. His symptoms improved with levodopa replacement, but dramatically worsened when enteral feeding was begun due to interference with intestinal absorption of levodopa.
Gordon
P H
PH
Department of Neurology, Columbia-Presbyterian Medical Center, New York, New York, USA.
Frucht
S J
SJ
D000328:Adult; D000978:Antiparkinson Agents / Q000009:adverse effects* / Q000493:pharmacokinetics; D006801:Humans; D007980:Levodopa / Q000009:adverse effects* / Q000493:pharmacokinetics; D008297:Male; D009459:Neuroleptic Malignant Syndrome / Q000209:etiology*; D010300:Parkinson Disease / Q000188:drug therapy*; D055502:Secondary Prevention; D012720:Severity of Illness Index; D013375:Substance Withdrawal Syndrome
D000978:Antiparkinson Agents; D007980:Levodopa